Key result
LCZ696 reduces death and HF hospitalization compared to enalapril.
Why the study?
Does LCZ696 reduce the risks of death and hospitalization for heart failure compared to enalapril in patients with heart failure?
Does LCZ696 reduce the risks of death and hospitalization for heart failure compared to enalapril in patients with heart failure?
LCZ696 (angiotensin-neprilysin inhibition) is superior to enalapril in reducing death and heart failure hospitalization in patients with heart failure.
Supports LCZ696 over enalapril for heart failure; confirms neprilysin inhibition reduces mortality and hospitalizations.
LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure. (Funded by Novartis; PARADIGM-HF ClinicalTrials.gov number, NCT01035255.).
No takes yet. Share an insight, caveat, or question.
McMurray et al. (2014) studied this question. LCZ696 was superior to enalapril in reducing the risks of death and hospitalization for heart failure in patients with heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: